TABLE 4.

Chest Radiographic Effective Dose Reported in Published Studies Compared With National Lung Screening Trial Assessment

Study or Location	Mean Effective Dose (mSv)	Reference	View	Effective Dose Variation
Dutch National Institute of Public Health (2004)	0.016	16	Posteroanterior	Coefficient of variation, 38%
National Radiological Protection Board, United Kingdom (1996)	0.017	17	Posteroanterior	Percentile (5th and 95th), 0.008–0.037 mSv
Nationwide Evaluation of X-ray Trends, chest radiography, United States (1984–2001)	0.026	18	Posteroanterior	SD, 0.001 mSv
National Lung Screening Trial, chest radiography, United States (2002–2007)	0.052		Posteroanterior	Percentile (5th and 95th), 0.013–0.136 mSv
UNSCEAR, Japan (2000)	0.057	19	Not reported	Variation range, 0.01–0.4 mSv
Switzerland (2002)	0.057	20	Posteroanterior	Relative error, 15%
Taiwan (2008)	0.06	21	Posteroanterior	Variability not reported
UNSCEAR, Netherlands (2000)	0.06	19	Not reported	Variation range, 0.01–0.4 mSv
UNSCEAR, Finland (2000)	0.10	19	Not reported	Variation range, 0.01–0.4 mSv
UNSCEAR, Norway (2000)	0.13	19	Not reported	Variation range, 0.01–0.4 mSv
UNSCEAR, Sweden (2000)	0.15	19	Not reported	Variation range, 0.01–0.4 mSv
UNSCEAR, Germany (2000)	0.30	19	Not reported	Variation range, 0.01–0.4 mSv

Note—UNSCEAR = United Nations Scientific Committee on the Effects of Atomic Radiation.